 | Fate Therapeutics (NASDAQ:FATE) Cut to "Strong Sell" at Zacks Investment Research
marketbeat.com - October 22 at 10:33 AM |
| BidaskClub Upgrades Fate Therapeutics (NASDAQ:FATE) to "Buy"
marketbeat.com - September 30 at 1:17 AM |
| Fate Therapeutics (NASDAQ:FATE) Stock Rating Upgraded by BidaskClub
marketbeat.com - August 21 at 1:04 AM |
| Technical Watchlist: Meritor, Banc of California, Fate Therapeutics (FATE)
marketbeat.com - August 3 at 2:08 PM |
 | Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
finance.yahoo.com - October 22 at 10:32 PM |
| Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting
finance.yahoo.com - October 22 at 10:32 PM |
 | Fate Therapeutics (NASDAQ:FATE) Shares Up 7.3%
americanbankingnews.com - October 22 at 7:52 PM |
| Fate Therapeutics (NASDAQ:FATE) Stock Price Down 7.7% Following Insider Selling
americanbankingnews.com - October 21 at 6:17 PM |
| Insider Selling: Fate Therapeutics Inc (NASDAQ:FATE) General Counsel Sells 29,199 Shares of Stock
americanbankingnews.com - October 20 at 5:07 PM |
| Reviewing MeiraGTx (NASDAQ:MGTX) and Fate Therapeutics (NASDAQ:FATE)
americanbankingnews.com - October 16 at 3:14 AM |
|
| Barclays Reaffirms "Overweight" Rating for Fate Therapeutics (NASDAQ:FATE)
americanbankingnews.com - October 15 at 9:12 AM |
 | A Closer Look At Fate Therapeutics
seekingalpha.com - October 12 at 5:14 PM |
| Fate Therapeutics (NASDAQ:FATE) Reaches New 12-Month High at $48.98
americanbankingnews.com - October 12 at 10:56 AM |
| Fate Therapeutics Inc. Register (F6T.SG)
au.finance.yahoo.com - October 10 at 1:19 AM |
| Fate Therapeutics (NASDAQ:FATE) Trading 6% Higher
americanbankingnews.com - October 7 at 9:03 PM |
| Fate Therapeutics (NASDAQ:FATE) Hits New 12-Month High at $42.27
americanbankingnews.com - October 6 at 10:46 AM |
| Fate Therapeutics (NASDAQ:FATE) Shares Gap Down to $40.61
americanbankingnews.com - October 5 at 9:43 AM |
| Fate Therapeutics (NASDAQ:FATE) Trading Down 6.2%
americanbankingnews.com - October 2 at 7:39 PM |
| Hedge Funds Have Never Been This Bullish On Eagle Materials, Inc. (EXP)
finance.yahoo.com - September 9 at 10:56 AM |
 | Protein Therapeutic Market 2020 Predictable to Witness Sustainable Evolution Over 2026
marketwatch.com - September 7 at 7:11 PM |
| Fate Therapeutics Announces September Investor Events
finance.yahoo.com - September 4 at 10:17 AM |
| Indapta Therapeutics Appoints Dov Goldstein, M.D., Chief Financial and Business Officer
finance.yahoo.com - August 31 at 11:45 PM |
 | Interesting FATE Put And Call Options For October 16th
nasdaq.com - August 25 at 2:40 PM |
| Fate Therapeutics gets new CFO
seekingalpha.com - August 19 at 10:52 AM |
| Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer
finance.yahoo.com - August 19 at 10:52 AM |
| How Much Of Fate Therapeutics, Inc. (NASDAQ:FATE) Do Institutions Own?
finance.yahoo.com - August 11 at 4:12 PM |
| What Kind Of Shareholders Own Fate Therapeutics, Inc. (NASDAQ:FATE)?
finance.yahoo.com - August 11 at 4:12 PM |
| Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 6 at 3:27 AM |
| Fate Therapeutics (FATE) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 5 at 10:27 PM |
| Fate Therapeutics EPS misses by $0.10, misses on revenue
seekingalpha.com - August 5 at 5:27 PM |
| Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress
finance.yahoo.com - August 5 at 5:27 PM |
| Fate Therapeutics Q2 2020 Earnings Preview
seekingalpha.com - August 4 at 9:24 PM |
|
| Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference
finance.yahoo.com - August 4 at 4:23 PM |
| Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
finance.yahoo.com - July 29 at 6:54 PM |
| Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
finance.yahoo.com - July 28 at 2:05 PM |
| Were Hedge Funds Right About Piling Into Fate Therapeutics Inc (FATE)?
finance.yahoo.com - July 16 at 2:38 PM |
| Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies
finance.yahoo.com - July 14 at 9:25 AM |
| Fate's IND Application for CAR T Cell Therapy Gets FDA Nod
finance.yahoo.com - July 10 at 1:26 PM |
| Fate Therapeutics on go to advance CAR T candidate FT819 into the clinic
seekingalpha.com - July 9 at 9:28 AM |
| Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy
finance.yahoo.com - July 9 at 9:28 AM |
| First Week of FATE February 2021 Options Trading
www.nasdaq.com - June 19 at 3:06 PM |
| Hedge Funds Keep Buying Fate Therapeutics Inc (FATE)
finance.yahoo.com - June 15 at 2:33 PM |
| If You Invested $1,000 in Fate Therapeutics' IPO, This Is How Much Money You'd Have Now
finance.yahoo.com - June 13 at 12:46 PM |
| Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - June 11 at 5:36 PM |
 | What does the future hold for the Fate Therapeutics Inc share price?
uk.finance.yahoo.com - June 10 at 10:12 AM |
| Here's Why Fate Therapeutics Rose 18.4% in May
finance.yahoo.com - June 9 at 6:32 PM |
 | BRIEF-Fate Therapeutics Announces Pricing Of Public Offering Of 6,181,562 Shares At A Price Of $28.31 Per Share
www.reuters.com - June 9 at 8:31 AM |
| Fate Therapeutics prices equity offering at $28.31
seekingalpha.com - June 9 at 8:31 AM |
| Fate Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - June 9 at 8:31 AM |
| Fate Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - June 8 at 7:40 PM |
| Global NK Cell Therapy Market 2020 Market Size, Business Opportunities, Current Trends, Share, Challenges and CAGR Status and Forecast to 2026
www.marketwatch.com - June 4 at 6:59 AM |
| FDA clears Fate Therapeutics' IND for FT538
seekingalpha.com - May 20 at 12:39 PM |
| Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy
finance.yahoo.com - May 20 at 12:39 PM |
 | Here's Why Big Buyers Are Excited About This Cancer Immunotherapy Stock
www.fool.com - May 15 at 8:57 AM |
